FindMyKOL
Clinical trialNCT01677013CompletedPhase 1/PHASE2Interventional

Autologous Bone Marrow Mononuclear Cell Transplantation in Treating Type 2 Diabetes Mellitus

SponsorPeking University Aerospace Center HospitalEnrollment1,026Type 2 Diabetes Mellitus
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The study is aimed to evaluate the safety and efficiency of autologous bone marrow mononuclear cell transplantation in treating selective patients with type 2 Diabetes Mellitus. We hypothesized that autologous bone marrow stem cell transplantation would promote β-cells regeneration by directly differentiated from the transplanted BMMCs or stimulate local stem cells regeneration and thus decrease or eliminate the need of exogenous insulin and improve β-cells function.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

  • Bin Wang, M.D.

    Division of Hematology and Endocrinology, Peking University Aerospace Centre Hospital

    Principal Investigator
  • Danping Meng, M.D.

    Division of Hematology and Endocrinology, Peking University Aerospace Centre Hospital

    Principal Investigator
  • Han Shi, M.D.

    Division of Hematology and Endocrinology, Peking University Aerospace Centre Hospital

    Principal Investigator
  • Hong Wang, M.D.

    Division of Hematology and Endocrinology, Peking University Aerospace Centre Hospital

    Principal Investigator
  • Lei Lei, M.D.

    Division of Hematology and Endocrinology, Peking University Aerospace Centre Hospital

    Principal Investigator
  • Liqin Cui, M.D.

    Division of Hematology and Endocrinology, Peking University Aerospace Centre Hospital

    Principal Investigator
  • Liyan Yang, M.D.

    Division of Hematology and Endocrinology, Peking University Aerospace Centre Hospital

    Principal Investigator
  • Mingchao Ding, M.D.

    Division of Hematology and Endocrinology, Peking University Aerospace Centre Hospital

    Principal Investigator
  • Qiuming Jiang, M.D.

    Division of Hematology and Endocrinology, Peking University Aerospace Centre Hospital

    Principal Investigator
  • Song Dong, M.D.

    Division of Hematology and Endocrinology, Peking University Aerospace Centre Hospital

    Principal Investigator
  • Xiaolin Jia, M.D.

    Division of Hematology and Endocrinology, Peking University Aerospace Centre Hospital

    Study Director
  • Xin Lin, M.D.

    Division of Hematology and Endocrinology, Peking University Aerospace Centre Hospital

    Principal Investigator
  • Xiyang Zhang, M.D.

    Division of Hematology and Endocrinology, Peking University Aerospace Centre Hospital

    Principal Investigator
  • Yizhong Wang, M.D., Ph.D.

    Division of Hematology and Endocrinology, Peking University Aerospace Centre Hospital

    Study Chair
  • Yuanjie Mao, M.D., Ph.D.

    Department of Biochemisty, National Cerebral and Cardiovascular Center; Department of Cardiology, China-Japan Friendship Hospital

    Study Director
  • Yufang Li, M.D.

    Division of Hematology and Endocrinology, Peking University Aerospace Centre Hospital

    Principal Investigator

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

China
  • Division of Hematology and Endocrinology, Peking University Aerospace Centre Hospital

    Beijing, Beijing Municipality, China

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study. It may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
31 May 2011
Primary completion
31 May 2015
Completion
31 Jul 2017
Last update posted
3 Oct 2017
Registered enrollment
1,026
Registry id
NCT01677013

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.